Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule
Status:
Recruiting
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
Soft tissue sarcoma STS is a group of malignant tumors derived from connective tissue other
than bone and cartilage. It can occur in any part of the body at any age, and there is no
significant gender difference.According to pathological classification, STS has 19 tissue
types and more than 50 disease subtypes.Currently, surgical resection, radiotherapy and drug
therapy are the main treatment methods.But about 50% of the patients with distant metastasis
happened not the surgical removal of, quite a number of in patients with distant metastasis
after died of disease progression 8-12 months in drug treatment of soft tissue sarcoma, the
current widely used chemotherapy regimens for ADM/IFO single-agent or joint IFO ADM is a line
of chemotherapy, in addition, paclitaxel, gemcitabine, dorsey race, it was also used for soft
tissue sarcomas of second-line chemotherapy scheme, however, for some special subtypes of
sarcoma,Such as myxoid liposarcoma, pleomorphic rhabdomyosarcoma, leiomyosarcoma, glandular
soft tissue sarcoma and superficial malignant fibrous histiocytoma, are not sensitive to
chemotherapy or low sensitivity.Therefore, how to improve the survival rate of these patients
is an urgent problem to be solved.
Anlootinib hydrochloride is a multi-target tyrosine kinase inhibitor that has shown good
efficacy in solid tumors such as NSCLC, ovarian cancer, soft tissue tumors, and medullary
thyroid cancer.Especially in the field of soft tissue sarcomas, the results of phase IIb
clinical data were satisfactory.Therefore, Investigator plan to conduct the study of
anrotenil hydrochloride capsule for the treatment of soft tissue sarcomas with first-line
chemotherapy failure (anthracycline)